Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Hebei Medical University Fourth Hospital is the lead sponsor of 44 current clinical trials in our China register. 29 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Iparomlimab and Tuvonralimab, Bevacizumab and Capecitabine. The most-studied condition is Breast Cancer.

ClinicalTrials.gov trials by status

Recruiting2966%
Not yet open1227%
Active, closed37%

Trials by phase

Phase 22966%
Observational716%
Phase 437%
Phase 125%
Phase 2/325%
Not applicable12%

Clinical trials sponsored by Hebei Medical University Fourth Hospital

44 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma NCT06646588 · Esophageal Neoplasms Drugs: Fruquintinib, Tislelizumab	Phase 2	Recruiting	2024-04	China
Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color） NCT06949111 · Colon Cancer Drugs: Capecitabine, Capox, Iparomlimab and Tuvonralimab	Phase 2	Recruiting	2025-05	China
Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC) NCT07289997 · ClinicalTrials.gov ↗ · AFP Gastric or Gastroesophageal Junction Adenocarcinoma, PD-1/CTLA-4, AFPGC Drug: Iparomlimab and Tuvonralimab	Phase 2	Recruiting	2025-09	China
Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer NCT07635342 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer Drugs: Cyclophosphamide, Paclitaxel （Albumin Bound）, Pyrotinib Maleate	Phase 2	Recruiting	2024-04	China
Cardiac Safety Management and Immune Microenvironment Changes After Thoracic Radiotherapy: A Prospective Observational Study NCT07669493 · ClinicalTrials.gov ↗ · MACE, Arrhythmia, Pericardial Effusion and Survival	Observational	Recruiting	2026-01	China
Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer NCT06435260 · ClinicalTrials.gov ↗ · Pancreatic Cancer Drug: Camrelizumab	Phase 2	Recruiting	2024-08	China
The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma NCT07290010 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma (ESCC) Drug: Iparomlimab and Tuvonralimab	Phase 2	Recruiting	2025-09	China
Construction and Evaluation of Tumor Immunotherapy and Organ Damage Early Warning System Based on Multi-omics NCT07131007 · ClinicalTrials.gov ↗ · Malignant Neoplasm, Organ Damage	Observational	Recruiting	2025-09	China
Clinical Study of Breast Conserving Surgery Combined With Intraoperative Radiotherapy for Early Breast Cancer NCT06375798 · ClinicalTrials.gov ↗ · Breast Cancer, HER2-negative Breast Cancer	Observational	Recruiting	2020-11	China
Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer NCT05241028 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Drug: Ensartinib	Phase 2	Recruiting	2022-05	China
Chemotherapy Combined With Bevacizumab Neoadjuvant Therapy for HER2-negative Breast Cancer NCT05525767 · ClinicalTrials.gov ↗ · Solid Tumor Drug: Bevacizumab	Phase 4	Recruiting	2022-03	China
Efficacy and Safety of Dalpiciclib in Hormone Receptor-positive Advanced Breast Cancer NCT05578053 · ClinicalTrials.gov ↗ · Breast Cancer Drug: Dalpiciclib	Observational	Recruiting	2024-09	China
SABR Combined With Axitinib and Toripalimab for Oligometastatic Renal Cell Carcinoma NCT07744932 · ClinicalTrials.gov ↗ · Oligometastatic Clear Cell Renal Cell Carcinoma Drugs: Axitinib, Toripalimab	Phase 2	Recruiting	2026-08	China
Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain Metastatic NCT06056115 · ClinicalTrials.gov ↗ · Lung Adenocarcinoma	Not applicable	Recruiting	2023-05	China
Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma NCT03964753 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	2019-04	China
Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC NCT07448077 · ClinicalTrials.gov ↗ · Efficacy and Safety of Short-course Radiotherapy in Total Neoadjuvant Therapy Combined With Enlonstobart for pMMR Locally Advanced Rectal Cancer	Phase 2	Recruiting	2026-03	China
Trilaciclib in Combination With Chemotherapy in Patients With CDK4/6-Dependent Solid Tumors NCT07490236 · ClinicalTrials.gov ↗ · Trilaciclib, CDK4/6-dependent Solid Tumors	Phase 1	Recruiting	2023-01	China
Real-world Study on the Prevention of Neutropenia After Tumor Treatment With Mecapegfilgrastim Injection NCT07434063 · ClinicalTrials.gov ↗ · Neutropenia Drug: Mecapegfilgrastim	Observational	Recruiting	2025-06	China
The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC). NCT06217185 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer, Advanced Breast Cancer Drugs: Capecitabine, Pyrotinib, Trastuzumab	Phase 4	Recruiting	2024-01	China
Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma NCT07179900 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma Drugs: Bevacizumab, Iparomlimab and Tuvonralimab, Sintilimab	Phase 2	Recruiting	2025-03	China
Minimally Residual of Esophageal Cancer 001 NCT05952661 · ClinicalTrials.gov ↗ · Esophageal Carcinoma, Minimal Residual Disease	Observational	Recruiting	2023-02	China
Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer NCT04138719 · ClinicalTrials.gov ↗ · Breast Cancer, Triple-negative Breast Cancer, Nab-paclitaxel Drugs: Carboplatin, Epirubicin, Nab-paclitaxel	Phase 2	Recruiting	2019-11	China
Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01) NCT06371482 · ClinicalTrials.gov ↗ · SCLC, Limited Stage Drug: Durvalumab	Phase 2	Recruiting	2023-06	China
Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer NCT04159142 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer, Nab-paclitaxel Drugs: Capecitabine, Carboplatin, Nab-paclitaxel	Phase 2	Recruiting	2019-11	China
Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer NCT06184698 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 2	Recruiting	2024-01	China
Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer NCT07492394 · ClinicalTrials.gov ↗ · Breast Cancer Drugs: Dalpiciclib, Entinostat, Letrozole	Phase 2	Recruiting	2025-09	China
Tumor Local Excision +Postoperative Adjuvant Chemoradiotherapy for T1-2N0M0 Low/Ultra-Low Rectal Cancer NCT06949098 · ClinicalTrials.gov ↗ · Rectal Cancer Stage I	Phase 2	Recruiting	2025-05	China
Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC） NCT06107673 · ClinicalTrials.gov ↗ · Breast Cancer Drugs: Cyclophosphamide, Dalpiciclib, Docetaxel	Phase 2	Recruiting	2023-09	China
Clinical Study of Adbelimumab in the Adjuvant Treatment of Esophageal Squamous Cell Carcinoma. NCT07266480 · ClinicalTrials.gov ↗ · Squamous Oesophageal Cancer	Phase 2	Recruiting	2025-09	China
Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR) NCT06903871 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma Stage II, Esophageal Squamous Cell Carcinoma Stage III Drug: Toripalimab	Phase 2	Not yet open	2025-04	China
Cadonilimab Combined With Anlotinib Followed by Radiotherapy in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (CAR-RMEC) NCT06681285 · ClinicalTrials.gov ↗ · Esophageal Carcinoma Drugs: Anlotinib, Cadonilimab	Phase 2	Not yet open	2024-11	China
Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell Carcinoma NCT07823270 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma Drugs: Sacituzumab tirumotecan, Toripalimab	Phase 2	Not yet open	2026-10	China
Becotatug Vedotin Plus Cisplatin and Radiotherapy in LA-ESCC NCT07697040 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma Drug: Becotatug Vedotin	Phase 1	Not yet open	2026-07	China
Paclitaxel Polymeric Micelles and Cisplatin Plus Sintilimab as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma NCT07799077 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma Drug: Sintilimab	Phase 2	Not yet open	2026-09	China
A Clinical Study of SHR-1701 Combined With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Siewert Type II Adenocarcinoma of the Esophagogastric Junction NCT07607210 · ClinicalTrials.gov ↗ · Siewert Type II Adenocarcinoma of the Esophagogastric Junction Drug: SHR-1701	Phase 2	Not yet open	2026-06	China
Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study NCT07004335 · ClinicalTrials.gov ↗ · PD-(L)1, CTLA-4, Advanced Melanoma Drugs: Bevacizumab, Iparomlimab and Tuvonralimab	Phase 4	Not yet open	2025-07	China
ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy NCT07410611 · ClinicalTrials.gov ↗ · Patients With Advanced Oligometastatic Non-small Cell Lung Cancer (NSCLC) Who Have Tested Positive for EGFR Mutations Confirmed by Histopathological Examination Drug: Befotertinib	Phase 2	Not yet open	2026-02	China
Tislelizumab in Combination with Chemotherapy ± Radiotherapy for Extensive-Stage Oligometastatic Small Cell Lung Cancer. NCT06851819 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Extensive Stage	Phase 2	Not yet open	2025-03	China
A Phase II Clinical Study of Induction Adebrelimab Combined With Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) NCT07112833 · ClinicalTrials.gov ↗ · Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma	Phase 2	Not yet open	2025-08	China
Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study. NCT07528898 · ClinicalTrials.gov ↗ · Breast Cancer Drugs: Pertuzumab, Trastuzumab, Trastuzumab Rezetecan	Phase 2	Not yet open	2026-05	China
A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal Cancer NCT07585279 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer (CRC), Liposomal Irinotecan, Second-Line Drugs: 5-FU/LV, Bevacizumab, Enlonstobart	Phase 2/3	Not yet open	2026-05	China
The Neoadjuvant Treatment Modalities in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (NEO-EC） NCT06828718 · ClinicalTrials.gov ↗ · Esophageal Carcinoma	Observational	Active, closed	2015-01	China
Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer NCT04290793 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2/3	Active, closed	2020-03	China
Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer NCT06210971 · ClinicalTrials.gov ↗ · Rectal Cancer Drugs: Capecitabine, Liposomal Irinotecan	Phase 2	Active, closed	2024-02	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Hebei Medical University Fourth Hospital trials

39 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Conditions in Hebei Medical University Fourth Hospital trials

48 conditions

Breast Cancer7 Esophageal Squamous Cell Carcinoma4 Esophageal Carcinoma3 HER2-positive Breast Cancer2Nab-paclitaxel2Esophageal Neoplasms1 Colon Cancer1AFP Gastric or Gastroesophageal Junction Adenocarcinoma1PD-1/CTLA-41AFPGC1Immunotherapy1Esophageal Squamous Cell Carcinoma Stage II1Esophageal Squamous Cell Carcinoma Stage III1MACE, Arrhythmia, Pericardial Effusion and Survival1Pancreatic Cancer1 Esophageal Squamous Cell Carcinoma (ESCC)1 Malignant Neoplasm1Organ Damage1HER2-negative Breast Cancer1 Non-small Cell Lung Cancer1 Solid Tumor1Siewert Type II Adenocarcinoma of the Esophagogastric Junction1PD-(L)11CTLA-41

By trial register

Register	Trials	Recruiting
Clinical trials in China	44	29

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Breast Cancer

Sponsor	Trials
Fudan University	48
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	21
Second Affiliated Hospital, Zhejiang University, School of Medicine	19
AstraZeneca	15
Shengjing Hospital	15
Pfizer	12
Sichuan Baili Pharmaceutical	12
Cancer Institute and Hospital, Chinese Academy of Medical Sciences	12
Hoffmann-La Roche	10
Ruijin Hospital	10

Sponsors with the most current trials registered for this condition.

Questions about Hebei Medical University Fourth Hospital trials

How many clinical trials does Hebei Medical University Fourth Hospital sponsor?

Hebei Medical University Fourth Hospital is the lead sponsor of 44 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Hebei Medical University Fourth Hospital trials recruiting?

Yes. 29 of its 44 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Hebei Medical University Fourth Hospital testing?

Its current trials name 39 drugs and biologicals as interventions. The most frequent are Iparomlimab and Tuvonralimab (5), Bevacizumab (4), Capecitabine (4), Dalpiciclib (3) and Toripalimab (3). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Hebei Medical University Fourth Hospital clinical trials